Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

GRCEBullishCorporate Developmentsnews

High materiality8/10

Grace Therapeutics secures $10 million private placement to extend runway to 2028

Aug 4, 2026, 9:03 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The private placement funds reduce burn and extend runway, improving execution probability for GTx-104; however, dilution may exert near-term pressure. The dual-manufacturing plan mitigates regulatory risk, supporting potential NDA timing improvements if readiness milestones are met.

AI summary

What happened, with direct paths to the underlying reporting

Grace Therapeutics (GRCE) announced a private placement expected to raise about $10 million by issuing 4.7619 million shares at $2.10 each, closing around August 6, 2026. Net proceeds will fund GTx-104 manufacturing and regulatory work, extending cash runway to the end of 2028. The company is pursuing a dual-source manufacturing strategy to mitigate FDA remediation risk, with NDA timing tied to readiness rather than remaining CRL issues alone.

Grace GRCE secures private placement for about $10M at $2.10/share.
Proceeds extend cash runway to end-2028 for GTx-104 development.
Dual-source manufacturing initiated to mitigate FDA remediation risk.
NDA resubmission timing hinges on manufacturing readiness, not CRL alone.
Close anticipated August 6, 2026.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Grace Therapeutics secures $10 million private placement to extend runway to 2028

Grace Therapeutics Faces FDA Setback but Plans to Resubmit GTx-104 NDA

Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study